Literature DB >> 18653425

Drug-risk communication to pharmacists: assessing the impact of risk-minimization strategies on the practice of pharmacy.

Lauren Y Lee1, Cindy M Kortepeter, Mary E Willy, Parivash Nourjah.   

Abstract

OBJECTIVES: To gain insight on the knowledge, opinions, barriers, and practices of pharmacists regarding drug risk-minimization tools.
DESIGN: Descriptive, nonexperimental, cross-sectional survey.
SETTING: 20 states in the United States, fall 2004. PARTICIPANTS: 2,052 randomly selected licensed pharmacists employed in a position requiring an active pharmacist license at the time of the survey and who responded to the survey. INTERVENTION: Participants completed a four-page survey regarding their experience with different types of risk-minimization tools. MAIN OUTCOME MEASURE: Univariate distributions for each question were analyzed.
RESULTS: 50% of survey recipients responded to the mailing; 88% of respondents had an active pharmacist license. Of respondents, 18% reported never having received a Dear Healthcare Professional letter and 29% stated that they were not familiar with Medication Guides. Patient package inserts were thought to be somewhat effective by 53% of respondents. Of pharmacists who dispensed a drug with programs for special stickers to be affixed on prescriptions to indicate that the labeled risk had been addressed by the prescriber, 41% reported receiving a prescription without a sticker; 45% dispensed the prescription when stickers were missing. Sixty percent of pharmacists stated that risk-minimization programs have a negative impact on the daily practice of pharmacy; nevertheless, many acknowledged that it was a necessary duty.
CONCLUSION: Pharmacists might benefit from additional training on risk-minimization strategies. The successful implementation and impact of risk-minimization programs on the practice of pharmacy should be carefully considered by drug manufacturers and regulators.

Entities:  

Mesh:

Year:  2008        PMID: 18653425     DOI: 10.1331/JAPhA.2008.07045

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  5 in total

1.  The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands.

Authors:  Sigrid Piening; Pieter A de Graeff; Sabine M J M Straus; Flora M Haaijer-Ruskamp; Peter G M Mol
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

2.  Relevance of a "Dear Doctor letter" to alert healthcare providers to new recommendations for vitamin D administration.

Authors:  Hélène Théophile; Ghada Miremont-Salamé; Philip Robinson; Nicholas Moore; Bernard Bégaud; Françoise Haramburu
Journal:  Eur J Clin Pharmacol       Date:  2011-05-20       Impact factor: 2.953

3.  Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

Review 4.  Amiodarone-associated optic neuropathy: a critical review.

Authors:  Rod S Passman; Charles L Bennett; Joseph M Purpura; Rashmi Kapur; Lenworth N Johnson; Dennis W Raisch; Dennis P West; Beatrice J Edwards; Steven M Belknap; Dustin B Liebling; Mathew J Fisher; Athena T Samaras; Lisa-Gaye A Jones; Katrina-Marie E Tulas; June M McKoy
Journal:  Am J Med       Date:  2012-03-03       Impact factor: 4.965

Review 5.  Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies.

Authors:  Lewis S Nelson; Meredith Loh; Jeanmarie Perrone
Journal:  J Med Toxicol       Date:  2014-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.